dc.contributorSofia Andrea Ahumada Antilao
dc.contributorPrestaciones Médicas Ayc Ltda.
dc.contributorServicios Cientificos Neuroinnovation Limitada
dc.date2014-05-29
dc.date2021-07-26T16:01:19Z
dc.date2021-07-26T16:01:19Z
dc.date.accessioned2022-12-27T07:20:51Z
dc.date.available2022-12-27T07:20:51Z
dc.identifier14IEAT-28666
dc.identifier2014-28666-INNOVA_PRODUCCION
dc.identifierhttp://repositoriodigital.corfo.cl:80/xmlui/handle/11373/323430
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5784046
dc.descriptionClinical Trial In Patients With Ad And Related Conditions.
dc.descriptionDevelopment Of Second Generation Tracers With Improved Imaging Properties.
dc.descriptionEvaluation Of First Generation Tracer In Healthy Volunteers.
dc.descriptionGmp-compliant Automated Radiosynthesis Of 18f-benzimidazoles For Human Application.
dc.descriptionThe General Objective Of the Project is To Develop An Advanced Pet Technology To Visualize Neurofibrillary Tangles (nft) a Key Lesion In the Brain Of Patients With Alzheimer´s Disease Which is the Product Of the Long-term Aggregation Of Abnormally-modified Tau Protein. We Have Discovered In the Past Decade That the Benzimidazoles Including Lansoprazole Specifically Bind To Nft. For This Reason We Will Use 18f-lansoprazole And Related Molecules As Radiopharmaceutical Probes To Specifically Tag Aggregated Tau And Nft In Order To Develop This Technology As a Biomarker For the Diagnosis Of Ad And Related Disorders. Such a Biomarker is Widely Felt To Be Essential For Early Diagnosis Together With Novel Therapies To Conquer Adrc. One Of the Main Shared Interests Between the Applicant And Collaborating Organizations is Neurodegenerative Disorders Including Their Diagnosis And Treatment. Both Organizations Would Therefore Benefit From Collaborating To Develop Products Relevant To Their Main Business Focus And To Enrich the National Capabilities In This Area With the Aim To Increase Their Competitiveness In the Global Market. In This Context It is Worth To Point Out That During the Last Decade Neuroimaging With Positron Emission Tomography (pet) Has Played a Main Role To a Better Understanding In Vivo Of the Pathophysiological Changes In Neurodegenerative Diseases Namely In Alzheimer's Disease (ad). Research Progress In Ad And Molecular Imaging Has Made Possible To Detect Human Brain B-amyloid (ba) Deposition Using Several Similar Biomarkers. However In Spite Of the Initial Enthusiasm Pet Imaging With B-amyloid Has Demonstrated Limited Clinical Applications. Although Ba Plaques Are One Of the Characteristic Features Of Ad Otherwise Normal Older Individuals Have Also Elevated Levels Of B-amyloid Similar To Ad Patients. Population-based Studies Estimate Positivity Rates For B-amyloid Pet Are Less Than 5% In Those 50 To 60 Years Old 10% In Those 60 To 70 Years Old 25% In Those 70 To 80 Years Old And More Than 50% In Persons Aged 80 To 90 Years (rowe Et Al. 2010). Therefore Considering the High Age-associated Prevalence Of B-amyloid In the Brain the Clinical Diagnostic Of Ad Based On the ?a Pet Findings. Another Example Of the Lack Of Specificity is the Presence Of Positive Amyloid Deposit Not Only In Ad But In Other Pathological Conditions Such As Dementia With Lewy Bodies (gomperts Et Al. 2008, Edison Et Al. 2008) Cerebral Amyloid Angiopathy Interstitial Fibrillar Amyloid In Plaques An Others. So It is Imperative To Highlight That Amyloid Positivity Does Not Determine the Diagnosis Of Ad. Due To the Above Mentioned Limitation Of B-amyloid Pet Imaging Novel Tracers With Better Specificity And Early Diagnostic Should Be Considered As a New Area In Ad.
dc.descriptionThis is a Project To Develop Innovative Radiopharmaceuticals To Visualize Neurofibrillary Tangles (nft) In Vivo In the Human Brain. Nft Are the Key Lesion In Alzheimer's Disease (ad) And Related Conditions (adrc) Which Ordinarily Can Only Be Seen At the Time Of Autopsy (which is Available Only In a Very Small And Rapidly Decreasing Number Of Cases Obviously Too Late To Be Useful Clinically). These Lesions Appear To Correspond To a Fundamental Step In a Sequence Of Pathological Events That Result From Tau Hyperphosphosphorylation And Its Self-association Into Oligomeric Structures And Filaments That so Far Can Only Be Visualized Employing Microscopes (and Thus Effectively Outside the Realm Of Virtually All Clinical Practice). Since There Are No In Vivo Markers Of Brain Lesions In Adrc In Clinical Use To Date We Will Develop Novel Radiopharmaceuticals To Visualize Nft Employing Benzimidazoles Based On Previous Research By Several Members Of Our Team. These Prior Investigations Have Created a Patent For a New Class Of Radiotracer Which Can Be Understood As a Repurposing Drugs-paradigm. In Combination With Their Documented Safety As Fdg Approved Agent And Long Precedence Of Human Application the Pharmacological Properties Of Lansoprazole And Astemizole Bode Very Well For Their Utility As Prospective Pet Radiotracer For Brain Imaging. In a Multidisciplinary Effort We Will Validate the Use Of This Novel Biomarker In Normal Human Subjects (controls) And Different Forms Of Dementia To Validate [a] Tracer Characteristics In Vivo [b] Its Capacity To Bind Specifically To Tau Deposits [c] Its Value As Diagnostic Tool In Ad. This Design Was Conceived To Accelerate the Application Of Benzimidazole-derived Radiomarkers For Nft In Humans Which is Indispensable For Them To Enter the Market And To Become the Much-sought-after New Standard For the Diagnosis Of Adrd. The Project Will Thus Lead To Much-needed Clinical Applications In the Diagnosis And Treatment Of Adrc With a Global Market Estimated In Excess Of a Billion Of Us Dollars Per Year And Help Position Chile At the Forefront Of Extremely Profitable Biomedical Technology For Neurodegenerative Disorders.
dc.descriptionCorporación de Fomento de la Producción
dc.titleRadiopharmaceutical To Visualize Neurofibrillary Tangles In Vivo
dc.typeproyecto


Este ítem pertenece a la siguiente institución